Davolink Amends Capital Increase Timeline: Payment and Listing Dates Delayed, Core Terms Unchanged
Davolink filed a correction on July 13, 2026 to its previously announced capital increase, delaying the payment date from July 13 to July 22 and the listing date from August 4 to August 13.
This amendment only reflects schedule changes; the key terms including 944,870 new shares, issue price of 1,020 won, total proceeds of approximately 963.8 million won, and the counterparty Medical Rich remain unchanged.
The dilution from the new shares is approximately 1.81%, a small amount, and the allocation to the third-party investor is maintained.
The company will use the proceeds for operating expenses, which are not linked to specific growth projects, limiting the positive impact on the stock price.
[AI Summary]This correction is a mere schedule delay, and since the capital increase terms are already finalized, there is no additional impact on existing shareholder value. The small dilution and an issue price above the current market price limit downside risk, but the use of funds for operational costs rather than growth initiatives is a negative factor.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)